Nymox gains patent for saliva cholesterol test:
This article was originally published in Clinica
Executive Summary
Nymox Pharmaceutical has received notice of issuance of a US patent covering its method and device for using saliva to determine cholesterol levels. The patent augments the firm's existing diagnostic platform technology pipeline, said the company, which uses its proprietary test technology in two products for determining tobacco exposure or use, NicAlert, a saliva/urine test, and TobacAlert, a urine test. The Maywood, New Jersey firm also makes AlzheimAlert, a urine test to help physicians diagnose Alzheimer's disease.
You may also be interested in...
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.